Background
In 2009, WHO has recommended to introduce HBV vaccine into the national immunization programs of endemic countries. Furthermore, HBV testing is recommended in all individuals living with HIV worldwide. This study sought to ascertain the burden of HIV/HBV co-infection and the HBV vaccine-induced immunisation in adolescents living with HIV-1 (ALHIV) receiving care in four West and Central African HBV-endemic countries.
Methods
Within the frame of the EVA network, the CABRILADO study was conducted among consenting ALHIV, aged 12-17 years and followed in eight pediatric centers located in Benin, Cameroon, Ivory Coast and Senegal. Clinical and sociodemographic parameters were collected and HBV-biomarkers were screened by a serological panel. Factors associated with vaccine immunisation were explored using a penalized logistic regression model.
Results
Overall, 638 ALHIV were enrolled, of whom 263 (41.2%) had already been screened for HBsAg since birth (undetected in all cases). A history of maternal HBV infection, of HBV in another household member and a personal history of HBV vaccination were observed in 1.3%, 0.8% and 16.9%, respectively.
Twenty-seven ALHIV were diagnosed with HIV/HBV coinfection (seroprevalence = 4.2% [95% CI: 2.8-6.1]), of whom the rate of active HBV infection (HBsAg+) was 1.1% [95% CI: 0.4-2.2]). Among 611 HBV-uninfected ALHIV, levels of anti-HBsAb were undetectable, poorly protective (1-9 IU/L) or protective (≥10 IU/L) in 452 (74.0%), 74 (12.1%) and 85 (13.9%) ALHIV, respectively. In the latter group, 36 ALHIV had strong seroprotection against HBV (anti-HBsAb ≥100 IU/L).
Compared to what observed in Benin, rates of HBV seroprotection (anti-HBsAb ≥10 IU/L) were lower in Cameroon (OR=0.30, 95%CI: 0.14-0.59) and Senegal (OR=0.44, 95%CI: 0.21-0.87) but higher in Ivory Coast (OR=1.36, 95%CI: 0.78, 2.38). Vaccine-induced immunization was not associated with sex, age, concomitant unsuppressed HIV viremia (pVL ≥50 cp/mL) or a history of HBV infection in the mother or any other household member.
Conclusions
Active HBV coinfection among ALHIV appears to be rare but frequently undiagnosed. The poor rate of HBV vaccine coverage and the scarcity of vaccine-induced protection highlight a persistent exposure to HBV and risks of developing liver disease in this vulnerable population. Significant efforts should be made to improve HBV screening and vaccine-induced immunisation in adolescents living with HIV in Western and Central Africa.